28
Participants
Start Date
December 31, 2015
Primary Completion Date
March 1, 2021
Study Completion Date
March 1, 2021
Enzalutamide
Enzalutamide with Sorafenib
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Westchester, Harrison
Washington University School of Medicine, St Louis
University of California San Francisco, San Francisco
Roswell Park Cancer Institute, Buffalo
Collaborators (1)
Astellas Pharma US, Inc.
INDUSTRY
Mayo Clinic
OTHER
University of California, San Francisco
OTHER
University of Southern California
OTHER
Washington University School of Medicine
OTHER
Roswell Park Cancer Institute
OTHER
National Comprehensive Cancer Network
NETWORK
Memorial Sloan Kettering Cancer Center
OTHER